CDC25 as a common therapeutic target for triple-negative breast cancer - the challenges ahead.

Autor:	Zacksenhaus, Eldad, Liu, Jeff C., Granieri, Letizia, Vorobieva, Ioulia, Wang, Dong-Yu, Ghanbari-Azarnier, Ronak, Li, Huiqin, Ali, Amjad, Chung, Philip E.D., Ju, YoungJun, Jiang, Zhe, Shrestha, Mariusz
Předmět:	BREAST cancer TUMORS PHOSPHATASES CLINICAL trials DISEASE progression
Zdroj:	Molecular & Cellular Oncology; 2018, Vol. 5 Issue 4, p1-1, 1p
Abstrakt:	The dual phosphatase CDC25 has recently been identified as a target for diverse triple-negative breast cancers including RB1/PTEN/P53-deficient tumors. Moreover, CDC25 inhibitors effectively synergize with PI3K inhibitors to suppress tumor growth. We discuss these findings and the challenges that lie ahead in bringing CDC25 inhibitors to the clinic. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.